Setup News Ticker
Searching for 'capital'. (Return)

MarketWatch MarketPulseMay 06, 2021
Regeneron stock rises, as profit, revenue and sales of SARS-CoV-2 antibody cocktail beat expectations
Shares of Regeneron Pharmaceuticals Inc. rose 0.8% in premarket trading Thursday, after the biotechnology company beat first-quarter profit and revenue expectations, with sales of its REGEN-COV antibody cocktail to the SARS-CoV-2 virus also topping forecasts. Net income rose to $1.12 billion, or $10.09 a share, from $625 million, or $5.43 a share, in the year-ago period. Excluding nonrecurring items, adjusted earnings per share grew to $9.89 from $6.60, beating the FactSet consensus of $8.68. Revenue increased 38% to $2.53 billion, topping the FactSet consensus of $2.50 billion, as REGEN-COV sales of $262 million beat expectations of $254.6 million. For 2021, the company cut its capital expenditures guidance range to $585 million to $650 million from $600 million to $680 million. The stock has lost 3.3% over the past three months through Wednesday, while the iShares Nasdaq Biotechnology ETF has dropped 11.9% and the S&P 500 has gained 7.2%.

Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit for more information on this news.

Google Market NewsMay 05, 2021
A day after losing father, T.J. Oshie nets a hat trick in Washington Capitals' emotional 4-2 victory - ESPN
A day after losing father, T.J. Oshie nets a hat trick in Washington Capitals' emotional 4-2 victory  ESPNRangers put NHL official on notice after Tom Wilson verdict: 'He is unfit to continue in his current role'  Fox NewsBrendan Smith Hunts Down Tom Wilson Seconds After Stepping Onto The Ice  SPORTSNETNew York Rangers, Washington Capitals square off with six fights in first period as Tom Wilson controversy carries over  ESPN

Washington Capitals vs. New York Rangers | EXTENDED HIGHLIGHTS | 5/5/2021 | NBC Sports - NBC Sports (Google Market News)
stockBuy earnings Dow expectations Futures
VaccineCOVID-19 Covid Patent backs Moderna
CovidCOVID-19 vaccine vaccines Moderna backs
Covid-19vaccine Vaccines Moderna Biden pandemic
StocksBuy Dow watch These Futures
earningsCall Transcript Q1 Inc stock
FacebookTrump Board Oversight ban decision
MarketStocks stock buy Dow Futures
TrumpFacebook Board Oversight ban decision

Top News (Business News)
Accounting Today
AdWeek News
Banking Business Review
Barron's This Week Magazine
Barron's Up and Down Wall Street Daily
Brad Ideas
Chicago Tribune Business News
CNBC Business
CNBC Economy
CNBC Finance
CNN/Money Real Estate News Analysis Indicators
Enterprise Application News
Forbes Headlines
Forbes Social Media News - China, Economy & Trade - Financial Markets - Hedge Funds - Telecoms - US
Google Business News
Google Market News
HBS Working Knowledge
INSEAD Knowledge
International Tax Review
L.S. Starrett News
MarketWatch Breaking News
MarketWatch MarketPulse
McKinsey Quarterly Business
Nielsen Trends
NonProfit Times
NPR Topics: Business
NYTimes Business
Private Equity Breaking News
Reuters Business
Reuters Company News
Reuters Money Updates: News Digest
Tax Policy News
The Economist International News
The Motley Fool
USA Today Money
Wall Street Journal US Business
Wall Street Transcript
Washington Post Business
WSJ Asia
WSJ Europe
WSJ MoneyBeat
WSJ Opinion
WSJ World Markets
Yahoo Business
  • CEOExpress
  • 1 Boston Place | Suite 2600
    Boston MA 02108
  • Contact
  • As an Amazon Associate
    CEOExpress earns from
    qualifying purchases.

©1999-2021 CEOExpress Company LLC